Phase II Study of Erlotinib, an Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin

Trial Profile

Phase II Study of Erlotinib, an Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2016

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jan 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2018, as reported by ClinicalTrials.gov.
    • 24 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.
    • 03 Mar 2014 Planned End Date changed from 1 Mar 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top